CBI "US Kineta Presents KVA12123 Phase 1/2 Clinical Trial Update at AACR"

CBI announced on the 19th that its investment company, the U.S. biotech firm Kineta, presented a poster on the immunosuppressive cell VISTA-related 'therapeutic efficacy1, biomarker' at the American Association for Cancer Research (AACR).

Dr. Thierry Guyodo, Chief Scientific Officer of Kineta, stated, "VISTA has been proven to be highly expressed in various types of tumor cells, including non-small cell lung cancer, colorectal cancer, cervical cancer, ovarian cancer, head and neck cancer, colon cancer, and kidney cancer. Kineta plans to collect tumor tissue and serum samples from cancer patients before treatment with KVA12123 in the ongoing Phase 1/2 clinical trial to highlight the importance of this biomarker."

He continued, "This work will help better understand the clinical response to KVA12123 in relation to VISTA expression levels not only in blood but also in tumor tissues, and the presence of VISTA expression opens up potential for the biomarker's therapeutic efficacy."

A CBI official said, "New data demonstrating that VISTA is particularly highly expressed in solid tumors was presented at this AACR, and the initiation of Phase 1/2 clinical trials to prove the efficacy of Kineta's VISTA antibody in cancer immunotherapy was simultaneously announced."

The official added, "Since Kineta is conducting Phase 1 and 2 trials concurrently, they are doing their best to announce results regarding safety and tolerability by the fourth quarter of this year."